Stephanie Spector
Family · Sarasota, FLNPI 1316458086
Payments from drug & device makers
Across 171 payments — averaging $37.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$866
- Abbott$850
- Biotronik Inc.$745
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$668
- Cvrx, Inc.$477
- Medtronic$472
- plus $2K from 27 others
What the payments were for
- Travel & lodging$2744%
- Food & beverage$6,12595%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 17 | $866 |
| Abbott | 18 | $850 |
| Biotronik Inc. | 13 | $745 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 33 | $668 |
| Cvrx, Inc. | 4 | $477 |
| Medtronic | 9 | $472 |
| Merz North America, Inc. | 6 | $407 |
| Johnson & Johnson(2 entities) | 16 | $362 |
| Kestra Medical Technology Services, Inc. | 9 | $194 |
| Biosense Webster, Inc. | 2 | $158 |
| Edwards Lifesciences | 1 | $142 |
| E.r. Squibb & Sons, L.L.C. | 1 | $122 |
| Galderma Laboratories, L.p. | 1 | $121 |
| Sanofi-aventis U.S. LLC | 5 | $103 |
| Merck | 3 | $86 |
| AstraZeneca | 6 | $85 |
| Bayer | 3 | $56 |
| Novartis | 2 | $56 |
| Elutia, Inc. | 4 | $51 |
| Geron Corporation | 2 | $49 |
| Novo Nordisk | 2 | $49 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $42 |
| Pfizer | 2 | $34 |
| Tersera Therapeutics LLC | 1 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Incyte Corporation | 1 | $27 |
| Bridgebio Pharma, Inc. | 1 | $27 |
| Boehringer Ingelheim | 1 | $21 |
| Puma Biotechnology, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Amgen | 1 | $19 |
| Convatec Inc. | 1 | $18 |
| Altathera Pharmaceuticals LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$459
- BioMonitor$418
- WATCHMAN FLX$283
- XEOMIN$280
- Quadra Allure MP RF CRT Pacemkr$168
- MERLIN@HOME$162
- PulseSelect$157
- Carto 3$125
- CAMZYOS$122
- Watchman$118
- Micra$111
- WATCHMAN Access System$111
- EnSite Precision Cardiac Mapping System$111
- COBALT DR MRI SURESCAN$111
- XARELTO$106
How this compares
$6,422 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 109 | $98,331 |
| XareltoRivaroxaban | 47 | $50,118 |
| MultaqDronedarone Hcl | 12 | $11,799 |
| Flecainide Acetate | 84 | $2,649 |
| Amiodarone Hcl | 104 | $1,437 |
| Metoprolol Succinate | 62 | $811 |
| Propafenone Hcl | 14 | $489 |
| Colchicine | 11 | $344 |
| Metoprolol Tartrate | 50 | $276 |
| SotalolSotalol Hcl | 14 | $235 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 13 | $177 |
| Digoxin | 15 | $126 |
| ClopidogrelClopidogrel Bisulfate | 11 | $104 |
| Carvedilol | 29 | $91 |
| Cephalexin | 17 | $64 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $34 | $98,331109 claims |
| Johnson & JohnsonXarelto | $362 | $50,11847 claims |
| Sanofi-aventis U.S. LLCMultaq | $103 | $11,79912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Sarasota
- Marie ZambelliSarasota$65K
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.